Eli Lilly (NYSE: LLY) reported Q1 2026 earnings that beat analyst estimates and raised its full-year guidance, sending the stock up 3.07% on April 30. Revenue is now projected between $82 billion and $85 billion. Non-GAAP EPS guidance was lifted to $35.50-$37.00. The primary driver: surging demand for GLP-1 weight loss drugs Mounjaro and Zepbound.
The Q1 numbers at a glance
Eli Lilly beat estimates across the board. Revenue growth exceeded consensus forecasts by a meaningful margin. The company raised its full-year outlook by $2 billion, signaling management confidence that demand will continue to accelerate through 2026. The guidance raise is particularly notable because it comes after a year where many analysts questioned whether GLP-1 growth was already priced in.
For income investors, the signal matters more than the headline number. A company that keeps raising guidance quarter after quarter demonstrates the kind of predictable earnings trajectory that supports long-term dividend growth. Eli Lilly’s trajectory suggests it can grow its dividend at double-digit rates for years to come.
| Metric | Q1 2026 Result | Prior Guidance | New Guidance |
|---|---|---|---|
| Revenue | Beat estimates | $80B-$83B | $82B-$85B |
| Non-GAAP EPS | Strong growth | ~$34-$36 | $35.50-$37.00 |
| Q1 post-earnings move | +3.07% | N/A | N/A |
| YTD stock performance | -11% | N/A | N/A |
| Current price range | $934-$968 | N/A | N/A |
GLP-1 drugs drive the growth engine
Mounjaro (for diabetes) and Zepbound (for obesity) now account for an estimated 50-60% of Eli Lilly’s revenue growth. Combined quarterly sales likely exceeded $10 billion. Supply chain improvements have allowed the company to fulfill more prescriptions, while expanded indications and new approvals in additional markets fuel momentum.
The weight loss drug market is projected to reach $100 billion annually by 2030. Eli Lilly and Novo Nordisk (NYSE: NVO) currently dominate, but competition from Amgen, Roche, and Viking Therapeutics is entering clinical trials. For now, Lilly’s first-mover advantage and manufacturing scale provide a meaningful moat.
Supply improvements deserve particular attention. In 2024 and 2025, shortage lists constrained GLP-1 revenue growth. With manufacturing capacity coming online, the supply bottleneck has eased, allowing the company to capture backlog demand that accumulated during the shortage period.
Analyst targets and valuation
Despite the strong Q1 report, Eli Lilly’s stock has fallen approximately 11% year-to-date. Some analysts view the decline as a buying opportunity. Street consensus sits around $1,198, implying roughly 24% upside from the $934-$968 range. More aggressive DCF-based models from TIKR suggest a midpoint target near $1,811.
The YTD decline likely reflects profit-taking after a multi-year rally and rotation away from mega-cap growth names. Investors who were waiting for an entry point may find the current pullback offers reasonable value relative to the growth trajectory management has demonstrated.
| Source | Current Price | Target | Implied Upside | Timeframe |
|---|---|---|---|---|
| Street consensus | ~$960 | ~$1,198 | ~24% | 12 months |
| 24/7 Wall St. | $934 | $1,133 | ~21% | 12 months |
| TIKR (DCF midpoint) | $963 | $1,811 | ~88% | 1-2 years |
What income investors should consider
Eli Lilly is not a traditional income stock. Its dividend yield sits below 1%, far lower than the 3-5% yields that income-focused investors typically seek. However, the company has increased its dividend for 10 consecutive years, and the growth trajectory suggests substantial dividend increases ahead as free cash flow expands.
For investors willing to accept a lower current yield in exchange for growth, Lilly offers a rare combination. Earnings growth above 25% annually, a wide competitive moat in GLP-1 drugs, and a management team demonstrating execution capability through consistent guidance raises.
A practical approach: size a Lilly position at 2-3% of a total portfolio. This provides exposure to the growth story without sacrificing current income from other holdings. A $500,000 portfolio with $12,500 in LLY at current prices owns approximately 13 shares generating roughly $90 in annual dividends — modest today, but likely to grow substantially as earnings expand.
GLP-1 competitive landscape
| Company | Drug | Status | Est. Launch |
|---|---|---|---|
| Eli Lilly | Mounjaro/Zepbound | Market leader | Approved |
| Novo Nordisk | Wegovy/Ozempic | Market leader | Approved |
| Amgen | MariTide | Phase 3 | 2027-2028 |
| Roche | CT-388 (oral) | Phase 2 | 2028+ |
| Viking Therapeutics | VK273 (oral) | Phase 2 | 2028+ |
Dollar-impact example for income investors
Consider two scenarios for a $500,000 retirement portfolio. Scenario A allocates 100% to high-yield dividend stocks averaging 4.5%. Scenario B allocates 97% to the same high-yield stocks and 3% to LLY. In Scenario A, annual income totals $22,500. In Scenario B, income drops to roughly $22,090 — a $410 reduction. But the 3% LLY position provides growth exposure that could appreciate 20-25% annually, potentially adding $7,500-$9,375 in capital gains. Over five years, the growth differential compounds significantly while the income sacrifice remains minimal.
Risks to watch
- Competition: Amgen, Roche, and Viking Therapeutics are developing next-generation weight loss drugs that could erode Lilly’s market share by 2028.
- Regulatory risk: Drug pricing legislation could pressure margins across the pharmaceutical sector.
- Valuation premium: Even after the YTD decline, LLY trades at a significant premium to pharma peers on a P/E basis.
- Supply constraints: While improving, manufacturing capacity limits could cap near-term revenue growth if demand continues to outpace production.
- Pipeline dependency: Revenue growth remains heavily concentrated in GLP-1 drugs. Any safety concern or clinical trial failure could trigger a sharp revaluation.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
